ENTX Overview

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Wall Street analysts forecast ENTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTX is10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Entera Bio Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Entera Bio Ltd. EPS for the last quarter amounts to -0.06 USD, decreased -0.00

Entera Bio Ltd (ENTX) has 20 emplpoyees as of April 19 2026.

Today ENTX has the market capitalization of 69.70M USD.